Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: The THP monotherapy study group trial

Journal of Clinical Oncology

Volumn 31, Issue 11, 2013, Pages 1422-1427

  Ito, Akihiro ^a   Shintaku, Ichiro ^a   Satoh, Makoto ^d   Ioritani, Naomasa ^b   Aizawa, Masataka ^b   Tochigi, Tatsuo ^e   Kawamura, Sadafumi ^e   Aoki, Hiroshi ^e   Numata, Isao ^f   Takeda, Atsushi ^f   Namiki, Shunichi ^f   Namima, Takashige ^c   Ikeda, Yoshihiro ^c   Kambe, Koichi ^g   Kyan, Atsushi ^h   Ueno, Seiji ⁱ   Orikasa, Kazuhiko ^a   Katoh, Shinnosuke ^j   Adachi, Hisanobu ^k   Tokuyama, Satoru ^l   Ishidoya, Shigeto ^a   Yamaguchi, Takuhiro ^a   Arai, Yoichi ^a   more..

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Sendai Shakaihoken Hospital   (Japan)

^c TOHOKU ROSAI HOSPITAL   (Japan)

^d Sen en General Hospital   (Japan)

^e Miyagi Cancer Center   (Japan)

^f Osaki Citizen Hospital   (Japan)

^g Senseki Hospital   (Japan)

^h Shirakawa Kosei General Hospital   (Japan)

ⁱ Kesennuma City Hospital   (Japan)

^j Ogachi Central Hospital   (Japan)

^k Iwate Prefectural Iwai Hospital   (Japan)

^l Iwaki Kyoritsu General Hospital   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PIRARUBICIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BLADDER CANCER; CONTROLLED STUDY; CYSTOSCOPY; CYTOPATHOLOGY; DRUG EFFICACY; FEMALE; HUMAN; LAPAROSCOPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEPHROURETERECTOMY; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; RECURRENT CANCER; SURGICAL APPROACH; TRANSITIONAL CELL CARCINOMA; UPPER URINARY TRACT UROTHELIAL CARCINOMA; URINARY TRACT CARCINOMA;

EID: 84876091536     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.2128     Document Type: Article

References (29)

1. Matsui Y, Utsunomiya N, Ichioka K, et al: Risk factors for subsequent development of bladder cancer after primary transitional cell carcinoma of the upper urinary tract. Urology 65:279-283, 2005 (Pubitemid 40248013)
2. Huang WW, Huang HY, Liao AC, et al: Primary urothelial carcinoma of the upper tract: Important clinicopathological factors predicting bladder recurrence after surgical resection. Pathol Int 59:642-649, 2009
3. O'Brien T, Ray E, Singh R, et al: Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: A prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial). Eur Urol 60:703-710, 2011
4. Takaoka E, Hinotsu S, Joraku A, et al: Pattern of intravesical recurrence after surgical treatment for urothelial cancer of the upper urinary tract: A single institutional retrospective long-term follow-up study. Int J Urol 17:623-628, 2010
5. Mullerad M, Russo P, Golijanin D, et al: Bladder cancer as a prognostic factor for upper tract transitional cell carcinoma. J Urol 172:2177-2181, 2004 (Pubitemid 39507486)
6. Sakamoto N, Naito S, Kumazawa J, et al: Prophylactic intravesical instillation of mitomycin C and cytosine arabinoside for prevention of recurrent bladder tumors following surgery for upper urinary tract tumors: A prospective randomized study. Int J Urol 8:212-216, 2001 (Pubitemid 34225056)
7. Wu WJ, Ke HL, Yang YH, et al: Should patients with primary upper urinary tract cancer receive prophylactic intravesical chemotherapy after nephroureterectomy? J Urol 183:56-61, 2010
8. Akaza H, Niijima T, Hisamatsu T, et al: Comparative investigation on use of (2″R)-4′-O-tetrahydropyranyladriamycin and adriamycin as intravesical chemotherapy for superficial bladder tumors. Urology 32:141-145, 1988
9. Yamamoto Y, Nasu Y, Saika T, et al: The absorption of pirarubicin instilled intravesically immediately after transurethral resection of superficial bladder cancer. BJU Int 86:802-804, 2000
10. Sylvester RJ, Oosterlinck W, van der Meijden AP: A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: A metaanalysis of published results of randomized clinical trials. J Urol 171:2186-2190, 2004 (Pubitemid 38625431)
11. Okamura K, Ono Y, Kinukawa T, et al: Randomized study of single early instillation of (2″R)-4′-O-tetrahydropyranyl-doxorubicin for a single superficial bladder carcinoma. Cancer 94:2363-2368, 2002 (Pubitemid 34457117)
12. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31:103-115, 1975
13. University Hospital Medical Information Network: UMIN Clinical Trials Registry: Trial number UMIN000004039. http://www.umin.ac.jp/ctr/index.htm
14. Habuchi T, Takahashi R, Yamada H, et al: Metachronous multifocal development of urothelial cancers by intraluminal seeding. Lancet 342:1087-1088, 1993 (Pubitemid 23338743)
15. Catto JW, Hartmann A, Stoehr R, et al: Multifocal urothelial cancers with the mutator phenotype are of monoclonal origin and require panurothelial treatment for tumor clearance. J Urol 175:2323-2330, 2006 (Pubitemid 43668524)
16. Hafner C, Knuechel R, Stoehr R, et al: Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies. Int J Cancer 101:1-6, 2002 (Pubitemid 34832989)
17. Harris AL, Neal DE: Bladder cancer: Field versus clonal origin. N Engl J Med 326:759-761, 1992
18. Boorjian SA: Postoperative intravesical therapy to prevent bladder tumor recurrence: Are we ready to listen yet? Eur Urol 60:711-712, 2011
19. Tolley DA, Parmar MK, Grigor KM, et al: The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: A further report with 7 years of follow up. J Urol 155:1233-1238, 1996 (Pubitemid 26081202)
20. Solsona E, Iborra I, Ricós JV, et al: Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: Short and long-term followup. J Urol 161:1120-1123, 1999 (Pubitemid 29426099)
21. Kobayashi M, Sugaya Y, Yuzawa M, et al: Appropriate intravesical retention time of pirarubicin concentration based on its level in tumor tissue, anti-tumor effect and side effect in intravesical instillation therapy for bladder tumor [in Japanese]. Gan To Kagaku Ryoho 25:1771-1774, 1998
22. Azémar MD, Comperat E, Richard F, et al: Bladder recurrence after surgery for upper urinary tract urothelial cell carcinoma: Frequency, risk factors, and surveillance. Urol Oncol 29:130-136, 2011
23. Kusuda Y, Miyake H, Terakawa T, et al: Gender as a significant predictor of intravesical recurrence in patients with urothelial carcinoma of the upper urinary tract following nephroureterectomy. Urol Oncol [epub ahead of print on August 6, 2011]
24. Kobayashi Y, Saika T, Miyaji Y, et al: Preoperative positive urine cytology is a risk factor for subsequent development of bladder cancer after nephroureterectomy in patients with upper urinary tract urothelial carcinoma. World J Urol 30:271-275, 2012
25. Hattori R, Yoshino Y, Gotoh M, et al: Laparoscopic nephroureterectomy for transitional cell carcinoma of renal pelvis and ureter: Nagoya experience. Urology 67:701-705, 2006
26. Gill IS, Sung GT, Hobart MG, et al: Laparoscopic radical nephroureterectomy for upper tract transitional cell carcinoma: The Cleveland Clinic experience. J Urol 164:1513-1522, 2000
27. Terakawa T, Miyake H, Muramaki M, et al: Risk factors for intravesical recurrence after surgical management of transitional cell carcinoma of the upper urinary tract. Urology 71:123-127, 2008 (Pubitemid 351173269)
28. Kume H, Teramoto S, Tomita K, et al: Bladder recurrence of upper urinary tract cancer after laparoscopic surgery. J Surg Oncol 93:318-322, 2006
29. Ni S, Tao W, Chen Q, et al: Laparoscopic versus open nephroureterectomy for the treatment of upper urinary tract urothelial carcinoma: A systematic review and cumulative analysis of comparative studies. Eur Urol 61:1142-1153, 2012